Consultant EndocrinologistDasman Diabetes InstituteKuwait, Hawalli, Kuwait
Disclosure information not submitted.
SUN-525 - Impact of Glucagon Like Peptide 1 Receptor Agonist Therapy on Glycemic Outcomes, Body Composition, and Insulin Requirements in Adults with Long Standing Type 1 Diabetes.
Sunday, June 14, 20269:00 AM - 4:00 PM CT
MON-562 - Dual Incretin Therapy as A Metabolic Optimization Strategy in Type 1 Diabetes with Obesity and MASLD: A Case Study .
Monday, June 15, 20269:00 AM - 2:00 PM CT
MON-736 - Impact of Reduced-Frequency Glucagon-Like Peptide-1 Receptor Agonist Therapy on Weight Loss and Body Composition: A Real-World 12-Month Study
.jpg)
.jpg)
